Early TIPS with covered stents versus standard treatment for acute variceal bleeding in patients with advanced cirrhosis: a randomised controlled trial

医学 肝硬化 意向治疗分析 肝移植 随机对照试验 门脉高压 内科学 人口 外科 经颈静脉肝内门体分流术 胃肠病学 移植 环境卫生
作者
Yong Lv,Zhiping Yang,Lei Liu,Kai Li,Chuangye He,Zhenyu Wang,Wei Bai,Wengang Guo,Tianlei Yu,Xulong Yuan,Hongbo Zhang,Huahong Xie,Liping Yao,Jianhong Wang,Tao Li,Qiuhe Wang,Hui Chen,Enxin Wang,Dongdong Xia,Bohan Luo
出处
期刊:The Lancet Gastroenterology & Hepatology [Elsevier]
卷期号:4 (8): 587-598 被引量:200
标识
DOI:10.1016/s2468-1253(19)30090-1
摘要

Background The survival benefit of early placement of transjugular intrahepatic portosystemic shunts (TIPS) in patients with cirrhosis and acute variceal bleeding is controversial. We aimed to assess whether early TIPS improves survival in patients with advanced cirrhosis and acute variceal bleeding. Methods We did an investigator-initiated, open-label, randomised controlled trial at an academic hospital in China. Consecutive patients with advanced cirrhosis (Child-Pugh class B or C) and acute variceal bleeding who had been treated with vasoactive drugs plus endoscopic therapy were randomly assigned (2:1) to receive either early TIPS (done within 72 h after initial endoscopy [early TIPS group]) or standard treatment (vasoactive drugs continued to day 5, followed by propranolol plus endoscopic band ligation for the prevention of rebleeding, with TIPS as rescue therapy when needed [control group]). Randomisation was done by web-based randomisation system using a Pocock and Simon's minimisation method with Child-Pugh class (B vs C) and presence or absence of active bleeding as adjustment factors. The primary outcome was transplantation-free survival, analysed in the intention-to-treat population, excluding individuals subsequently found to be ineligible for enrolment. This study is registered with ClinicalTrials.gov, number NCT01370161, and is completed. Findings From June 26, 2011, to Sept 30, 2017, 373 patients were screened and 132 patients were randomly assigned to the early TIPS group (n=86) or to the control group (n=46). After exclusion of three individuals subsequently found to be ineligible for enrolment (two patients in the early TIPS group with non-cirrhotic portal hypertension or hepatocellular carcinoma, and one patient in the control group due to non-cirrhotic portal hypertension), 84 patients in the early TIPS group and 45 patients in the control group were included in the intention-to-treat population. 15 (18%) patients in the early TIPS group and 15 (33%) in the control group died; two (2%) patients in the early TIPS group and one (2%) in the control group underwent liver transplantation. Transplantation-free survival was higher in the early TIPS group than in the control group (hazard ratio 0·50, 95% CI 0·25–0·98; p=0·04). Transplantation-free survival at 6 weeks was 99% (95% CI 97–100) in the early TIPS group compared with 84% (75–96; absolute risk difference 15% [95% CI 5–48]; p=0·02) and at 1 year was 86% (79–94) in the early TIPS group versus 73% (62–88) in the control group (absolute risk difference 13% [95% CI 2–28]; p=0·046). There were no significant differences between the two groups in the incidence of hepatic hydrothorax (two [2%] of 84 patients in the early TIPS group vs one [2%] of 45 in the control group; p=0·96), spontaneous bacterial peritonitis (one [1%] vs three [7%]; p=0·12), hepatic encephalopathy (29 [35%] vs 16 [36%]; p=1·00), hepatorenal syndrome (four [5%] vs six [13%]; p=0·10), and hepatocellular carcinoma (four [5%] vs one [2%]; p=0·68). There was no significant difference in the number of patients who experienced other serious adverse events (ten [12%] vs 11 [24%]; p=0·07) or non-serious adverse events (21 [25%] vs 19 [42%]; p=0·05) between groups. Interpretation Early TIPS with covered stents improved transplantation-free survival in selected patients with advanced cirrhosis and acute variceal bleeding and should therefore be preferred to the current standard of care. Funding National Natural Science Foundation of China, National Key Technology R&D Program, Optimized Overall Project of Shaanxi Province, Boost Program of Xijing Hospital.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
脑洞疼应助steleegee采纳,获得10
刚刚
1秒前
成就心锁发布了新的文献求助10
1秒前
1秒前
tuetue发布了新的文献求助20
3秒前
3秒前
5秒前
6秒前
CipherSage应助虚幻亦竹采纳,获得10
6秒前
史俊美完成签到 ,获得积分20
6秒前
6秒前
tumbler发布了新的文献求助10
7秒前
清风慕竹发布了新的文献求助10
7秒前
大个应助成就心锁采纳,获得10
8秒前
MY999完成签到,获得积分10
8秒前
dui完成签到,获得积分10
9秒前
Esty发布了新的文献求助10
10秒前
Xyx发布了新的文献求助10
10秒前
bkagyin应助黄辉冯采纳,获得10
11秒前
科研通AI5应助湛湛采纳,获得10
11秒前
steleegee发布了新的文献求助10
12秒前
Lin关闭了Lin文献求助
12秒前
脑洞疼应助郑镲桂采纳,获得10
14秒前
冷酷瑾瑜完成签到,获得积分10
15秒前
15秒前
斯文败类应助Xyx采纳,获得10
15秒前
16秒前
脑洞疼应助ZHAO采纳,获得10
17秒前
玮丶关注了科研通微信公众号
17秒前
18秒前
19秒前
Lucas应助ss采纳,获得10
20秒前
shuaixiaoyu完成签到,获得积分10
20秒前
21秒前
科研通AI5应助火星上初柳采纳,获得10
21秒前
丘比特应助tuetue采纳,获得10
22秒前
Rui发布了新的文献求助10
23秒前
25秒前
黄辉冯发布了新的文献求助10
25秒前
雪霁完成签到,获得积分10
25秒前
高分求助中
(禁止应助)【重要!!请各位详细阅读】【科研通的精品贴汇总】 10000
求polyinfo中的所有数据,主要要共聚物的,有偿。 1500
Mechanics of Composite Strengthening 1500
International Code of Nomenclature for algae, fungi, and plants (Madrid Code) (Regnum Vegetabile) 1500
Robot-supported joining of reinforcement textiles with one-sided sewing heads 800
水产动物免疫学 500
鱼类基因组学及基因组物种技术 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4176574
求助须知:如何正确求助?哪些是违规求助? 3711838
关于积分的说明 11705529
捐赠科研通 3394692
什么是DOI,文献DOI怎么找? 1862417
邀请新用户注册赠送积分活动 921170
科研通“疑难数据库(出版商)”最低求助积分说明 833056